1. Home
  2. SATL vs REPL Comparison

SATL vs REPL Comparison

Compare SATL & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Satellogic Inc.

SATL

Satellogic Inc.

HOLD

Current Price

$5.32

Market Cap

529.2M

Sector

Technology

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$13.65

Market Cap

454.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SATL
REPL
Founded
2010
2015
Country
United States
United States
Employees
154
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.2M
454.6M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SATL
REPL
Price
$5.32
$13.65
Analyst Decision
Strong Buy
Hold
Analyst Count
3
9
Target Price
$5.50
$5.67
AVG Volume (30 Days)
5.3M
6.9M
Earning Date
05-12-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$88.89
N/A
Revenue Next Year
$56.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$1.50
52 Week High
$12.00
$13.90

Technical Indicators

Market Signals
Indicator
SATL
REPL
Relative Strength Index (RSI) 61.28 62.64
Support Level $4.52 $6.80
Resistance Level $6.03 N/A
Average True Range (ATR) 0.38 1.55
MACD 0.31 0.41
Stochastic Oscillator 78.05 95.72

Price Performance

Historical Comparison
SATL
REPL

About SATL Satellogic Inc.

Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: